Welcome to our dedicated page for RAD news (Ticker: RAD), a resource for investors and traders seeking the latest updates and insights on RAD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RAD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RAD's position in the market.
Rite Aid (NYSE: RAD) emphasizes the importance of flu and COVID-19 vaccinations ahead of Halloween as early seasonal influenza cases rise, according to the CDC. The pharmacy encourages community members to stay updated with vaccines, highlighting that both the flu shot and updated COVID-19 booster are essential for protection. Customers can schedule vaccinations online and benefit from promotional coupons. With an expected active flu season, Rite Aid aims to ensure public health while making the vaccination process convenient for all.
Rite Aid (NYSE: RAD) is enhancing diagnostic testing accessibility in Michigan by offering rapid point-of-care testing for Strep A and combined Flu A/B and COVID-19 at all stores. Customers can receive quick results and prescriptions on-site without an appointment, catering to individuals aged four and older. While currently available in Michigan, Rite Aid plans to expand testing to other states. This initiative addresses increased demand for flu and respiratory illness testing as the colder months approach, aligning with the company's commitment to improved health outcomes.
Rite Aid (NYSE: RAD) is now offering updated boosters of the Pfizer-BioNTech and Moderna COVID-19 vaccines for children aged five and older, following FDA authorization and CDC guidelines. Appointments can be scheduled online, and both vaccines aim to enhance protection against original strains and Omicron subvariants. Additionally, Rite Aid encourages customers to get flu shots by Halloween, as per CDC recommendations. The updated boosters can be mixed and matched with previous vaccines, enhancing convenience for families seeking immunization.
Rite Aid has revealed key findings on Halloween candy preferences, showing that chocolate remains dominant in seasonal sales. Last Halloween, over 2.8 million pounds of candy were sold, with M&M’S, Reese’s Peanut Butter Pumpkins, and MILKY WAY topping the list. Interestingly, 45% of candy purchases occurred in the week leading up to Halloween, indicating consumer procrastination. Additionally, Rite Aid promotes inclusivity by encouraging the use of teal pumpkins for allergy-friendly treats. Shoppers are also purchasing Halloween décor alongside candy.
Rite Aid (NYSE: RAD) has partnered with Google Cloud to enhance its pharmacy operations through advanced technology. This multi-year partnership aims to modernize Rite Aid's services by migrating applications to Google Cloud's Anthos platform, improving customer engagement and operational resilience. Key initiatives include migrating enterprise data to BigQuery for better decision-making, enhancing search capabilities on its e-commerce platforms, and updating the pharmacy benefits management system. This strategic investment reflects Rite Aid's commitment to redefining the pharmacy experience.
Rite Aid Corporation (NYSE: RAD) reported second-quarter revenues of $5.9 billion, a decline from $6.1 billion in the previous year. The company experienced a significant net loss of $331.3 million or $6.07 per share, influenced by a $252.2 million goodwill impairment charge. Adjusted EBITDA fell to $78.5 million from $106.2 million year-over-year. Retail comparable prescriptions rose 3.1%, with acute prescriptions growing 5.3%. The outlook for fiscal 2023 projects revenues between $23.6 billion and $24.0 billion but an increased net loss estimate between $520.3 million and $477.3 million.
Rite Aid announced the appointment of Steve Bixler as the new Chief Accounting Officer, effective January 13, 2023. He replaces Brian Hoover, who is retiring after 27 years with the company, including three years in this role. Bixler has been with Rite Aid for over 21 years, most recently as Vice President of Financial Accounting since 2020. CFO Matt Schroeder expressed confidence in Bixler's leadership during the transition as the company aims to modernize its pharmacy services.
Rite Aid Corporation (NYSE: RAD) will announce its financial results for Fiscal 2023 Second Quarter, ending August 27, 2022, on September 29, 2022, at 8:30 a.m. ET. An analyst call will follow, providing insights from management. The call will be accessible via broadcast and replay options.
As a leading full-service pharmacy, Rite Aid operates over 2,350 retail locations across 17 states, employing more than 6,400 pharmacists. Its services include retail and delivery pharmacy, pharmacy benefits through Elixir, and healthcare coaching via Health Dialog.
Rite Aid (NYSE: RAD) has announced the availability of updated booster doses for the Pfizer and Moderna COVID-19 vaccines at its locations and at Bartell Drugs in the Pacific Northwest. Eligible individuals aged 12 and up can schedule appointments via Riteaid.com and Bartelldrugs.com. The vaccine is designed to offer protection against the original strains and Omicron BA.4 and BA.5 subvariants. Rite Aid encourages customers to obtain flu shots simultaneously with their COVID-19 vaccinations.
Rite Aid (NYSE: RAD) has partnered with WellSpan Health to enhance health outcomes for patients in central Pennsylvania and northern Maryland. The collaboration will focus on sharing data to improve care continuity, boost immunizations, and enhance medication adherence. The joint efforts aim to provide innovative care models and clinical services aimed at chronic disease management and preventative medicine. Rite Aid serves over 100,000 customers annually through this collaboration across 45 locations, underlining its commitment to redefining the pharmacy experience.